N-苄基-4-(4-苯氧基苯基)-4-哌啶醇 | 202604-70-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: N-苄基-4-(4-苯氧基苯基)-4-哌啶醇
• 英文名称: N-benzyl-4-(4-phenoxyphenyl)-4-piperidinol
• 英文别名: 1-benzyl-4-(4-phenoxy-phenyl)-piperidin-4-ol；1-benzyl-4-(4-phenoxyphenyl)piperidin-4-ol
• CAS: 202604-70-4
• 化学式: C₂₄H₂₅NO₂
• 分子量: 359.468
• InChiKey: IAMUULJFSZYSJB-UHFFFAOYSA-N

物化性质

• 沸点：
  516.2±50.0 °C(Predicted)
• 密度：
  1.174±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  32.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-苄基-4-(4-苯氧基苯基)-4-哌啶醇 在 palladium 10% on activated carbon 三氟乙酸 、 氢气 作用下， 以 甲醇 为溶剂， 75.0~130.0 ℃ 、400.01 kPa 条件下， 反应 5.25h， 以92%的产率得到4-(4-苯氧基苯基)-哌啶
  参考文献：
  名称：

  [EN] ANTHELMINTIC AGENTS AND THEIR USE
  [FR] AGENTS ANTHELMINTHIQUES ET LEUR UTILISATION

  摘要：

  该发明涉及一般用作驱虫剂或作为制备驱虫剂中间体的化合物和盐。该发明还涉及制备这些化合物和盐的工艺、包含这些化合物和盐的药物组合物和工具包、使用这些化合物和盐制作药物以及将这些化合物和盐用于需要治疗的动物的治疗方法。

  公开号：

  WO2009077527A1
• 作为产物：
  描述：

  N-苄基哌啶酮 、 4-苯氧基苯基溴化镁 在 盐酸 、 水 、 碳酸氢钠 作用下， 以 四氢呋喃 、 乙醚 、 水 为溶剂， 以33%的产率得到N-苄基-4-(4-苯氧基苯基)-4-哌啶醇
  参考文献：
  名称：

  [EN] ANTHELMINTIC AGENTS AND THEIR USE
  [FR] AGENTS ANTHELMINTIQUES ET LEUR UTILISATION

  摘要：

  这项发明涉及一般用作驱虫剂或作为制备驱虫剂的中间体的化合物和盐。这项发明还涉及制备这些化合物和盐的方法，包括这些化合物和盐的药物组合物和试剂盒，使用这些化合物和盐制备药物，以及将这些化合物和盐用于需要治疗的动物的治疗方法。

  公开号：

  WO2010115688A1

文献信息

• ANTHELMINTIC AGENTS AND THEIR USE
  申请人：Chassaing Christophe Pierre Alain

  公开号：US20110319393A1

  公开（公告）日：2011-12-29

  This invention is directed to compounds and salts that are generally useful as anthelmintic agents or as intermediates in processes for making anthelmintic agents. This invention also is directed to processes for making the compounds and salts, pharmaceutical compositions and kits comprising the compounds and salts, uses of the compounds and salts to make medicaments, and treatments comprising the administration of the compounds and salts to animals in need of the treatments.

  本发明涉及化合物和盐，通常可用作驱虫剂或作为制备驱虫剂的中间体。本发明还涉及制备这些化合物和盐的过程，包括这些化合物和盐的药物组合物和试剂盒，使用这些化合物和盐制备药物，并将这些化合物和盐用于治疗需要治疗的动物的治疗方法。
• Anthelmintic agents and their use
  申请人：Chassaing Christophe Pierre Alain

  公开号：US08569495B2

  公开（公告）日：2013-10-29

  This invention is directed to compounds and salts that are generally useful as anthelmintic agents or as intermediates in processes for making anthelmintic agents. This invention also is directed to processes for making the compounds and salts, pharmaceutical compositions and kits comprising the compounds and salts, uses of the compounds and salts to make medicaments, and treatments comprising the administration of the compounds and salts to animals in need of the treatments.

  本发明涉及一些化合物和盐，它们通常用作驱虫剂或作为制造驱虫剂的中间体。本发明还涉及制造这些化合物和盐的过程，包括这些化合物和盐的药物组合物和试剂盒，使用这些化合物和盐制造药物，以及将这些化合物和盐用于需要治疗的动物的治疗。
• ARYLPIPERIDINOL AND ARYLPIPERIDINE DERIVATIVES AND DRUGS CONTAINING THE SAME
  申请人：SUNTORY LIMITED

  公开号：EP0867183A1

  公开（公告）日：1998-09-30

  A pharmaceutical composition, especially a pharmaceutical composition for the alleviation or treatment of symptoms due to ischemic diseases and symptoms derived from seizures, epilepsy, and migraine, and a Ca2+ overload suppressant, containing an arylpiperidinol or arylpiperidine derivative having the formula (I): wherein, R is H, an optionally substituted phenyl, an optionally substituted phenoxy, or an optionally substituted benzoyl, A is a connecting bond, a cycloalkylene, or an alkenylene optionally substituted with a lower alkyl, B is an alkylene optionally substituted with OH or an alkoxy or -NHCO(CH2)n- where n is an integer of 1 to 5, E is a connecting bond, O, or a methylene, X is OH or H provided that when E is O or a methylene, X is not H, and Y and Z are independently H, a halogen, an alyoxy, or an alyyl optionally substituted with a halogen.

  一种药物组合物，特别是一种用于缓解或治疗缺血性疾病引起的症状和癫痫发作、癫痫和偏头痛引起的症状的药物组合物，以及一种Ca2+超载抑制剂，含有具有式(I)的芳基哌啶醇或芳基哌啶衍生物： 其中，R 是 H、任选取代的苯基、任选取代的苯氧基或任选取代的苯甲酰基，A 是连接键、环烷基或任选被低级烷基取代的烯基、B 是任选被 OH 或烷氧基或-NHCO(CH2)n-取代的亚烷基，其中 n 是 1 至 5 的整数；E 是连接键、O 或亚甲基；X 是 OH 或 H，但当 E 是 O 或亚甲基时，X 不是 H；Y 和 Z 独立地是 H、卤素、烯丙基氧基或任选被卤素取代的烯丙基。
• Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same
  申请人：——

  公开号：US20030130312A1

  公开（公告）日：2003-07-10

  A pharmaceutical composition, especially a pharmaceutical composition for the alleviation or treatment of symptoms due to ischemic diseases and symptoms derived from seizures, epilepsy, and migraine, and a Ca 2+ overload suppressant, containing an arylpiperidinol or arylpiperidine derivative having the formula (I): 1 wherein, R is H, an optionally substituted phenyl, an optionally substituted phenoxy, or an optionally substituted benzoyl, A is a connecting bond, a cycloalkylene, or an alkenylene optionally substituted with a lower alkyl, B is an alkylene optionally substituted with OH or an alkoxy or —NHCO(CH 2 ) n — where n is an integer of 1 to 5, E is a connecting bond, O, or a methylene, X is OH or H provided that when E is O or a methylene, X is not H, and Y and Z are independently H, a halogen, an alkoxy, or an alkyl optionally substituted with a halogen.

  一种药物组合物，特别是一种用于缓解或治疗缺血性疾病引起的症状以及癫痫发作、癫痫和偏头痛引起的症状的药物组合物，以及一种 Ca 2&plus； 过载抑制剂，含有具有式（I）的芳基哌啶醇或芳基哌啶衍生物： 1 其中，R 是 H、任选取代的苯基、任选取代的苯氧基或任选取代的苯甲酰基；A 是连接键、环烷基或任选被低级烷基取代的烯基；B 是任选被 OH 或烷氧取代的烷基或 -NHCO(CH 2 ) n - 其中 n 是 1 至 5 的整数，E 是连接键、O 或亚甲基，X 是 OH 或 H，但当 E 是 O 或亚甲基时，X 不是 H，Y 和 Z 独立地是 H、卤素、烷氧基或任选被卤素取代的烷基。
• Synthesis and biological evaluation of new 4-arylpiperidines and 4-aryl-4-piperidinols: dual Na+ and Ca2+ channel blockers with reduced affinity for dopamine D2 receptors
  作者：Hirokazu Annoura、Kyoko Nakanishi、Mayumi Uesugi、Atsuko Fukunaga、Seiichi Imajo、Atsuko Miyajima、Yoshiko Tamura-Horikawa、Shigeki Tamura

  DOI：10.1016/s0968-0896(01)00288-7

  日期：2002.2

  A series of novel 4-arylpiperidines and 4-aryl-4-piperidinols (2a-f, 3a f and 4a-f) wits synthesized and evaluated for blocking effects on both neuronal Na+ and T-type Ca2+ channels and binding affinity for dopamine D-2 receptors. Most or the compounds blockaded both ion channels with potency greater than or equal to flunarizine Ia which was adopted as a reference standard. In addition, these compounds had significantly reduced affinity for dopamine D-2 receptors which is common in this class of structure. Compounds 2a-f, 3a-f and 4a-f exhibited potent anticonvulsant effects following systemic (ip) administration on audiogenic seizures in DBA/2 mice, indicating their excellent brain permeability. The neuroprotective activity of 2a, 3a and 4a was also assessed in a transient middle cerebral artery Occlusion (MCAO) model. These Compounds significantly reduced neuronal damage without affecting ischemic hyperthemia, while flunarizine Ia produced only minor reductions. In particular. 4a had 1.7-fold the potency in this MCAO model but only 1/20 the affinity for dopamine D-2 receptors of 1a. The Superposition of 2a, 3a and 4a on the basis of analyses of systematic conformation and similar structure has revealed that the cinnamyl, phenacyl and phenoxy-propanol groups are likely to be structurally and biologically equivalent. Moreover, the Superposition of 2a and 2f shows that diphenyl ether and biphenyl groups occupy a similar space, suggesting that both groups act as a bioisostere for the blockade of ion channels: however, this is not the case for dopamine D-2 receptors since only biphenyl Compounds such as 2f had high affinity similar to flunarizine Ia. Compound 4a (SUN N5030) has a good pharmacological profile and may be Useful in the alleviation and treatment or ischemic diseases. (C) 2001 Elsevier Science Ltd. All rights reserved.